1.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 20050113, NCT00243685
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI
Protocol IDs: COG-ARST0331, NCT00075582, ARST0331
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 30 at diagnosis
Sponsor: NCI
Protocol IDs: COG-ARST0332, ARST0332, NCT00346164
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI
Protocol IDs: COG-ARST0531, NCT00354835, ARST0531
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: CRUK-VORTEX, EU-20678, ISRCTN76456502, CRCTU-SA3002, NCT00423618
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08SARC01, NCT00870701
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: CWS-2007-HR, 4033024 (BfArM), 293/2007AMG1 (Ethikkommission), 2007-001478-10 (EUDRACT), A2007/14 (Kinderkrebsstiftung), 498 (Krebsstudienregister), NCT00876031
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DUMC-1308-04-7R5, DUMC-G040102, DUMC-G880018, NCT00093509
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: ASSG01, NCT00753727
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCDCC-216, UCDCC#216, BAYER-UCDCC-216, NCT00805727
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PXD101-CLN-14, NCT00878800
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: MSKCC-03099, NCT00077285
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 25 and under
Sponsor: Other
Protocol IDs: RTSARC, NCT00186992
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 03-0107-C, NCT00188175
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-04S1, NCT00288015
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 05-090, 1 R21 CA117128-01A1, NCT00356031
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0630, RTOG 0630, NCT00589121
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: 04-188, NCT00592592
|
|
21.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-07216, 07216, NCT00740597
|
|
22.
|
Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TRC105499, TRC105499, NCT00358540
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-03740, NCT00580320
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NYU 05-409, NCT00821652
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAD4523, NCT01010958
|
